InflaRx
Controlling Inflammation - developing drugs to treat life threatening and chronic inflammatory diseases
49 employees · est. 2007 · Jena, Germany
Tridek-One
We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases
12 employees · est. 2018 · Paris, France
InflaRx is the older company (2007 vs 2018).
Side-by-Side Comparison
| Metric | InflaRx | Tridek-One |
|---|---|---|
| Founded | ||
| Founded | 2007 older | 2018 |
| Headquarters | ||
| Headquarters | Jena, Germany | Paris, France |
| Employees | ||
| Employees | 49 | 12 |
| Industry | ||
| Industry | Health Care, Health and Wellness, Pharmaceutical | Biotechnology, Health Care, Life Sciences |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | Series Unknown |
| Total Funding | ||
| Total Funding | $250.20M | $19.00M |
| Funding Rounds | ||
| Funding Rounds | 9 | 2 |
| Services | ||
| Services | Development of anti-C5a and C5aR inhibitors, Clinical trials for inflammatory diseases, Research and development of transformative treatments, Commercialization of complement system inhibitors | Development of first-in-class CD31 checkpoint agonists for the treatment of autoimmune and inflammatory diseases. |
| Target Customers | ||
| Target Customers | Hospitals treating COVID-19 patients, Healthcare providers, Pharmaceutical industries, Investors in biotechnology | Patients with autoimmune and inflammatory diseases, healthcare providers, pharmaceutical companies, and biotech research institutions. |
| Taxonomy | ||
| Taxonomy | Biopharmaceutical, Anti-Inflammatory Therapeutics, Anti-C5a Technology, Monoclonal Antibody Development, Chronic Inflammatory Diseases, Complement Activation Inhibitors, Vilobelimab, Oral Small Molecule Inhibitors, C5aR Technology, Acute Inflammation Treatment, Clinical Trials, Drug Discovery, Immunology Research, Complement System Modulation | Immunomodulation, Therapeutic Antibodies, Autoimmune Diseases, Inflammatory Disorders, Biopharmaceuticals, Immunotherapy, Drug Development, Immune Checkpoint Modulation, Monoclonal Antibodies, Immunological Research, Therapeutic Innovation, Immune System Modulation, Clinical Development, Autoimmune Therapy |
| Website | ||
| Website | inflarx.de | tridekone.com |
About InflaRx
InflaRx, founded in 2007, is a Germany-based biopharmaceutical company recognized for pioneering anti-inflammatory therapeutics. The company's slogan, "Controlling Inflammation - developing drugs to treat life threatening and chronic inflammatory diseases," clearly reflects its mission. At the core...
About Tridek-One
Tridek-One is a French biotechnology startup founded in 2018, specializing in the development of first-in-class therapeutic agonistic monoclonal antibodies targeting immune checkpoint inhibitory receptors for the treatment of autoimmune and inflammatory diseases. The company's focus on anti-CD31 ago...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at InflaRx and Tridek-One — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at InflaRx and Tridek-One — by email.
Frequently Asked Questions
Compare InflaRx with someone else
Start typing a company name or domain.